AUSTRALIA | Macular Disease Foundation Australia has welcomed the TGA approval for eye injection treatment SYFOVRE.
The Therapeutic Goods Administration (TGA) approval of the new eye injection treatment SYFOVRE (pegcetacoplan) is welcomed by the Macular Disease Foundation, as it will give many people with Geographic Atrophy a treatment option that they’ve never had before to slow the progression of the disease. This is a long-awaited positive development for the macular disease community, who to date have had limited treatment options.
Macular Disease Foundation Australia supports thousands of people living with the devastating impacts of Geographic Atrophy, which can include irreversible and severe loss of their central vision. Geographic Atrophy, also known as late “dry” age-related macular degeneration, is a progressive disease of the macula. It is one of two forms of late-stage age-related macular degeneration (AMD).
This approval of SYFOVRE by the TGA is significant as it means the treatment has been independently assessed as being a safe and effective treatment to reduce the impact of Geographic Atrophy on people, their families and carers.
People with Geographic Atrophy should be aware, however, that this outcome doesn’t necessarily mean that they will be eligible for treatment with SYFOVRE, or that the treatment will be suitable for them. Macular Disease Foundation recommends people consult their ophthalmologist, who will need to weigh-up the benefits and risks to determine if the new treatment is suitable for them.
Macular Disease Foundation recommends people who have been diagnosed with Geographic Atrophy continue seeing their eye health professional as often as they recommend and not skip appointments. They should also continue to have any tests that their eye health professional recommends to ensure that the progress of their Geographic Atrophy is regularly monitored.
The association is the national peak body that represents the interests of the more than eight million Australians who live with, or are at risk of contracting, macular disease, as well as supporting their families.
More news here.
